Related Experiment Video

Updated: May 1, 2026

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.0K

Molecular Bases for the Regulation of NKG2D Ligands in Cancer

Leticia Huergo-Zapico1, Andrea Acebes-Huerta1, Alejandro López-Soto1

  • 1Department of Functional Biology, University Institute of Oncology (IUOPA), University of Oviedo , Oviedo , Spain.

Frontiers in Immunology
|April 9, 2014
PubMed

Insights

Natural killer group 2D (NKG2D) receptor ligands initiate anti-tumor immunity but are counter-regulated by cancer cells. This review integrates pathways regulating NKG2D ligand expression and immune evasion in cancer.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • NKG2D is an activating receptor on NK and T cells, crucial for eliminating transformed and infected cells.
  • NKG2D ligands, normally restricted in healthy tissues, are induced by cancer-associated signaling pathways.
  • Tumorigenic processes upregulate NKG2D ligands, triggering an immune response against nascent tumors.

Purpose of the Study:

  • To review and integrate the mechanisms and pathways regulating NKG2D ligand expression in cancer.
  • To explore how cancer cells evade NKG2D-mediated immune surveillance.

Main Methods:

  • Literature review of studies on NKG2D receptor and ligand biology.
  • Analysis of signaling pathways involved in NKG2D ligand induction and regulation.
  • Examination of cancer immunoediting and immune evasion mechanisms related to NKG2D.

Main Results:

  • NKG2D ligand expression is induced by proliferative, tumor suppressor, and stress pathways during tumorigenesis.
  • Advanced tumors develop immune evasion mechanisms, often involving counter-regulation of NKG2D ligands.
  • The redundancy of NKG2D ligands complicates their regulation and may hinder effective immune evasion strategies.

Conclusions:

  • NKG2D-mediated anti-tumor immunity is a critical early defense but is ultimately subverted by cancer.
  • Understanding the complex regulation of NKG2D ligands is key to developing novel cancer immunotherapies.
  • Further research into NKG2D ligand redundancy and immune evasion is warranted.
Keywords:
MICAMICBNK cellNKG2DT cellsULBPregulationsignaling pathways

More Related Videos

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

21.0K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.2K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.3K